DE-089 ophthalmic solution + DE-089 ophthalmic solution + Placebo ophthalmic solution
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedAbout DE-089 ophthalmic solution + DE-089 ophthalmic solution + Placebo ophthalmic solution
DE-089 ophthalmic solution + DE-089 ophthalmic solution + Placebo ophthalmic solution is a phase 2 stage product being developed by Santen Pharmaceutical for Dry Eye. The current trial status is completed. This product is registered under clinical trial identifier NCT01189032. Target conditions include Dry Eye.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01189032 | Phase 2 | Completed |
Competing Products
20 competing products in Dry Eye
Other Products from Santen Pharmaceutical
Eybelis ophthalmic solution 0.002%Approved
85
Aflibercept Injection [Eylea]Approved
85
STN1012600 ophthalmic solution 0.002% + STN1012600 ophthalmic solution 0.002% + STN1012600 ophthalmic solution 0.002% and Timolol ophthalmic solution 0.5%Phase 3
77
DE-117B Eye Drops + LatanoprostPhase 3
77
3% DE-089 ophthalmic solution + 0.1% sodium hyaluronate ophthalmic solutionPhase 3
77